AthenaEyes

AthenaEyes (智慧眼科技股份有限公司), headquartered in Changsha, Hunan Province, has evolved from a biometric recognition specialist into a broad-portfolio AI healthcare enterprise. The company develops AI-powered solutions for traditional Chinese medicine (TCM) diagnostics, medical insurance supervision, and digital health management, serving government agencies, healthcare institutions, and pharmaceutical retail chains across more than 20 provinces in China.

Company Overview

Founded in April 2009, AthenaEyes initially focused on computer vision and biometric authentication technologies, including facial recognition and finger vein identification. The company achieved international recognition when its finger vein recognition algorithms won the global ICB-CFVR challenge three consecutive years from 2015 to 2017. In 2016, AthenaEyes ranked second in Google’s MegaFace million-scale face recognition benchmark.

The company listed on China’s National Equities Exchange and Quotations (NEEQ, stock code: 836147) in March 2016, though it has since delisted. AthenaEyes maintains research centers in Beijing for algorithm development, Changsha for data operations, and Shenzhen for hardware design and manufacturing.

In recent years, AthenaEyes has pivoted toward healthcare AI applications, leveraging its computer vision and natural language processing expertise to develop medical diagnostic tools and health management platforms.

Core Products

Bianshi TCM Four Diagnosis Robot

The flagship medical product from AthenaEyes, the Bianshi (砭石) TCM Four Diagnosis Robot digitalizes the traditional Chinese medicine diagnostic process of inspection, auscultation, inquiry, and pulse-taking. Powered by the company’s proprietary Bianshi large language model, the system guides patients through tongue examination, facial analysis, and pulse diagnosis, completing the entire assessment in approximately five minutes.

The device generates full health reports that include constitution classification, health risk indicators, and personalized wellness recommendations. According to the company, the diagnostic accuracy matches that of a TCM practitioner with 8-10 years of clinical experience.

Bianshi Medical Large Language Model

Released in May 2023, Bianshi is described as the world’s first multimodal medical foundation model, supporting consultation text data, medical imaging, and patient audio data. The model powers various applications including AI clinical assistants, electronic medical record quality control, infectious disease surveillance, and patient health management platforms.

AthenaEyes has invested significantly in computing infrastructure to support model development, with training capacity reaching 400P and plans for a dedicated medical AI computing center with 1000P capacity.

Technology & Innovation

AthenaEyes maintains core competencies in computer vision, natural language processing, knowledge graphs, and privacy-preserving computation. The company holds national-level “Specialized, Refined, Differential and Innovative” (专精特新) enterprise certification, awarded in August 2022.

The Bianshi model employs multimodal fusion techniques to integrate TCM diagnostic data streams, combining visual analysis of tongue and facial features with pulse wave signals and patient-reported symptoms to generate holistic health assessments.

Market Presence

For chain pharmacies, community health centers, and primary care clinics, AthenaEyes deploys its Bianshi Four Diagnosis Robot to extend TCM diagnostic capability where qualified practitioners are scarce.

The Bianshi Four Diagnosis Robot has been deployed in Hunan Province, Chongqing, and other regions across China. Target application scenarios include:

• Chain pharmacies seeking to offer value-added health services
• Community health management centers
• Primary healthcare institutions with limited TCM specialist availability
• Wellness and preventive care facilities

The company positions the product as a tool to address healthcare resource imbalances by extending TCM diagnostic capabilities to grassroots medical facilities where qualified practitioners are scarce.

Key Milestones

• 2009: Company founded in Changsha
• 2015-2017: Consecutive global championships in finger vein recognition (ICB-CFVR)
• 2016: Listed on NEEQ; ranked second in Google MegaFace challenge
• 2022: Recognized as national-level “Specialized and Innovative” SME
• 2023: Released Bianshi multimodal medical large language model
• 2025: Featured at World Artificial Intelligence Conference (WAIC); selected for Forbes China AI Top 50

Frequently Asked Questions

What is the Bianshi TCM Four Diagnosis Robot?

The Bianshi Four Diagnosis Robot is an AI-powered medical device that digitizes traditional Chinese medicine diagnostic methods. It performs automated tongue examination, facial analysis, and pulse diagnosis, then generates health assessment reports with constitution classification and wellness recommendations.

Is AthenaEyes a publicly traded company?

AthenaEyes was previously listed on China’s NEEQ (National Equities Exchange and Quotations) under stock code 836147, but has since delisted. The company has completed multiple funding rounds through Series B.

Where is the Bianshi system deployed?

The Bianshi Four Diagnosis Robot has been deployed in healthcare facilities, pharmacies, and health management centers across Hunan Province, Chongqing, and other Chinese provinces. The company targets grassroots medical institutions seeking to provide TCM services without specialized practitioners.